=

Nordstrom’s New York flagship opens today. Here’s a look inside

At Nordstrom’s new store in Manhattan, you can get your hair and nails done, sip a cocktail while you shop for shoes, have your pants altered and leather shoes shined. The retailer hopes it’s enough to lure New Yorkers and tourists out to shop.

Ford’s shares slide on lower year-end guidance, weak demand in China

The quarterly earnings are the first since Moody’s Investors Service downgraded Ford’s credit rating to junk status in September.

Tesla’s stock is surging but some analysts found real problems with its earnings report

Shares of Tesla are surging after the company reported a surprise profit, but a closer look at the numbers may suggest a cause for concern.

Chemicals maker Dow cuts costs as global slowdown bites

Dow Inc. beat Wall Street estimates for profit in the third quarter as it cut costs to offset a sharp slowdown in demand for the chemicals it makes for plastics and other manufacturing.

Israeli fashion mogul submits bid for Barneys, challenging Authentic Brands

Israeli businessman Samuel Ben-Avraham said on Wednesday he has submitted an offer for Barneys New York, challenging a $271 million bid for the bankrupt luxury department store from brand developer Authentic Brands Group.

J&J slashes third-quarter profit by $3 billion over proposed opioid deal

Johnson & Johnson on Wednesday lowered its previously reported third-quarter profit by $3 billion to account for a proposed opioid settlement payment.

Workers at large GM plant in Michigan approve contract

Workers at one of the largest General Motors factories have voted to ratify a new contract with the company, an indication that a five-week strike could be coming to an end.

GlaxoSmithKline gets regulatory nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers.

Teva’s proposed opioid settlement could cost drugmaker pennies on the dollar

Teva Pharmaceutical’s proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review.